List of Excipients in Branded Drug PREMPRO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	PREMPRO	conjugated estrogens and medroxyprogesterone acetate	50090-0573	CARNAUBA WAX
A-S Medication Solutions	PREMPRO	conjugated estrogens and medroxyprogesterone acetate	50090-0573	CELLULOSE, MICROCRYSTALLINE
A-S Medication Solutions	PREMPRO	conjugated estrogens and medroxyprogesterone acetate	50090-0573	FERRIC OXIDE YELLOW
A-S Medication Solutions	PREMPRO	conjugated estrogens and medroxyprogesterone acetate	50090-0573	FERROSOFERRIC OXIDE
A-S Medication Solutions	PREMPRO	conjugated estrogens and medroxyprogesterone acetate	50090-0573	HYDROXYPROPYL CELLULOSE
A-S Medication Solutions	PREMPRO	conjugated estrogens and medroxyprogesterone acetate	50090-0573	HYPROMELLOSE 2208

PREMPRO Excipient Strategy and Commercial Opportunities

Last updated: August 2, 2026

PREMPRO is an oral, fixed-dose hormone replacement product containing conjugated estrogens and medroxyprogesterone acetate. Its main commercial protection is no longer expected to come from core composition patents or regulatory exclusivity. The strongest opportunities are generic or authorized-generic substitution, excipient modernization, dose-flexible platforms, manufacturing-cost reduction, and differentiated products for patients with excipient sensitivities.

PREMPRO’s excipient strategy is commercially relevant because the product combines low-dose hormones with multiple strengths, film coating, color differentiation, and long-term tablet stability requirements. A competing product must match pharmaceutical performance while controlling hormone uniformity, dissolution, content stability, packaging, and patient acceptability.

What is PREMPRO and which excipients does it contain?

PREMPRO is Pfizer’s continuous-combination oral hormone therapy. Each tablet contains conjugated estrogens and medroxyprogesterone acetate in fixed strengths. The product is indicated for menopausal vasomotor symptoms and vulvar and vaginal atrophy associated with menopause, and for prevention of postmenopausal osteoporosis in appropriate patients when alternatives are unsuitable. [1]

PREMPRO strengths and active ingredients

Product strength	Conjugated estrogens	Medroxyprogesterone acetate	Dosage form
PREMPRO 0.3 mg/1.5 mg	0.3 mg	1.5 mg	Oral film-coated tablet
PREMPRO 0.45 mg/1.5 mg	0.45 mg	1.5 mg	Oral film-coated tablet
PREMPRO 0.625 mg/2.5 mg	0.625 mg	2.5 mg	Oral film-coated tablet
PREMPRO 0.625 mg/5 mg	0.625 mg	5 mg	Oral film-coated tablet

The active pharmaceutical ingredients are conjugated estrogens and medroxyprogesterone acetate. Conjugated estrogens are a multicomponent mixture of estrogenic substances rather than a single chemically defined estrogen molecule. That characteristic creates formulation and analytical challenges that differ from conventional single-API generic tablets. [1,2]

What inactive ingredients are reported for PREMPRO?

The current U.S. labeling identifies inactive ingredients that include lactose monohydrate, microcrystalline cellulose, hypromellose, magnesium stearate, and coating-related materials. The exact composition can vary by strength and by manufacturing or labeling revision. The tablets use film coatings for appearance, identification, and protection. [1]

The principal excipient functions are:

Excipient class	Function in PREMPRO-type tablets	Commercial relevance
Lactose monohydrate	Diluent and tablet-bulk former	Creates an opportunity for lactose-free alternatives
Microcrystalline cellulose	Compressibility and tablet structure	Supports direct compression and mechanical strength
Magnesium stearate	Lubrication during compression	Excess use can affect wetting and dissolution
Hypromellose	Film-forming coating polymer	Supports coating integrity and appearance
Pigments or colorants	Strength identification and product recognition	May require separate regulatory and patient-acceptability review
Plasticizer or coating aid	Coating flexibility and processability	Affects coating defects, moisture barrier, and scale-up

The exact excipient formula is not the sole determinant of generic equivalence. The sponsor must demonstrate pharmaceutical equivalence and bioequivalence through an FDA-acceptable abbreviated new drug application pathway. [3]

How does the PREMPRO excipient strategy affect generic development?

A generic PREMPRO product must reproduce the relevant quality attributes of a low-dose, combination, film-coated tablet. The formulation challenge is not simply blending two APIs with standard tablet fillers.

Low-dose uniformity

The estrogen component is present at submilligram-to-low-milligram quantities. At these concentrations, segregation, adhesion to processing equipment, and inadequate blend uniformity can create potency variability. The formulation must control:

• API particle-size distribution
• Blend time and shear
• Order of addition
• Lubrication time
• Hopper residence time
• Tablet weight variation
• Content uniformity across commercial batches

Medroxyprogesterone acetate is present at a higher dose in some strengths, but the ratio between the two active ingredients changes across the product line. A single platform process may not perform identically for all strengths.

Dissolution and wetting

Hydrophobic drug particles, magnesium stearate, coating polymers, and compression force can affect tablet wetting and dissolution. A competitor may improve performance by adjusting:

• The lubricant concentration
• Granulation versus direct compression
• Particle-size control
• Disintegrant selection
• Tablet porosity
• Film-coat weight
• Packaging moisture control

A formulation that dissolves too slowly can create bioequivalence risk. A formulation that dissolves too quickly may create a different in vitro profile that requires additional justification.

Stability of a multicomponent estrogen product

Conjugated estrogens are a mixture of related estrogenic compounds. Stability programs must evaluate the individual components, total estrogenic content, degradation products, and assay methods. Excipient-related risks include:

• Oxidation
• Moisture uptake
• Interaction with pigments or coating components
• Adsorption to processing surfaces
• Light exposure
• Packaging-induced changes
• API-excipient incompatibility

Blister packaging, high-density polyethylene bottles, desiccants, and improved moisture barriers can become part of the commercial differentiation strategy.

What formulation opportunities exist for PREMPRO competitors?

The most practical opportunities are incremental. A competitor does not need to create a new active ingredient to obtain commercial value.

Lactose-free PREMPRO alternative

Lactose is a common tablet diluent, but some patients avoid lactose because of intolerance, allergy concerns, or personal preference. A lactose-free product could substitute:

• Mannitol
• Anhydrous dibasic calcium phosphate
• Pregelatinized starch
• Coprocessed cellulose systems
• Low-moisture spray-dried excipients

The replacement must preserve tablet hardness, disintegration, dissolution, blend uniformity, and stability. A lactose-free claim would have commercial value only if supported by a consistent formulation and accurate labeling.

Reduced-magnesium-stearate formulation

Magnesium stearate is effective at low concentrations but can impair dissolution when over-lubrication occurs. A competitor could evaluate:

• Lower lubricant loading
• Shorter lubrication time
• Sodium stearyl fumarate
• Alternative process aids
• Granulation strategies that reduce lubricant dependence

The commercial benefit would be stronger process robustness rather than a direct patient-facing claim.

Direct-compression platform

A direct-compression platform could reduce granulation equipment, solvent use, cycle time, and manufacturing cost. Microcrystalline cellulose and selected coprocessed excipients may provide the necessary compactibility.

The principal risks are blend segregation and dose uniformity because the active ingredients are present at different concentrations. A direct-compression approach is most attractive when the sponsor can maintain one validated manufacturing platform across all strengths.

Improved film coating

Film-coat optimization can support:

• Better tablet identification
• Reduced chipping and picking
• Lower coating weight
• Improved moisture protection
• More efficient high-speed coating
• Removal of unnecessary colorants

A coating change is commercially useful when it improves manufacturing yield or reduces patient confusion among strengths. It does not automatically create patent protection.

Packaging as part of the formulation strategy

Because PREMPRO is used chronically, packaging can affect adherence and stability. Commercial options include:

• Calendar blister packs
• Unit-dose packaging
• Moisture-resistant bottles
• Child-resistant systems
• Hospital or institutional packaging
• Lower-cost bulk bottles for pharmacy dispensing

Packaging differentiation can support contracting and adherence programs, although it generally provides weaker exclusivity than a patentable formulation or delivery system.

What patents protect PREMPRO and when does exclusivity end?

PREMPRO’s original product and regulatory exclusivity periods expired many years ago. The product was approved in the United States in 1995 under NDA 020544. [1,4]

Protection category	PREMPRO position
New chemical entity exclusivity	Expired
Original product patent protection	Expired or commercially obsolete
FDA orphan-drug exclusivity	Not applicable
Biologic exclusivity	Not applicable
Pediatric exclusivity	No current commercial significance
Core composition-of-matter protection	Not available for a mature combination product
Current commercial barrier	Manufacturing, bioequivalence, supply, quality, and market access

A current Orange Book review is necessary to identify any active listed patents for a specific NDA and strength. The principal competitive issue for a generic PREMPRO product is generally ANDA approval and commercial execution rather than remaining core patent life. [4]

Are PREMPRO formulations protected by patents?

A formulation patent could cover a specific excipient combination, dissolution profile, particle-size distribution, coating system, or stability improvement. Such claims would need to be evaluated against:

• Listed Orange Book patents
• Unlisted formulation patents
• Continuation applications
• Patent-term adjustments
• Patent-term extensions
• Paragraph IV certifications
• Invalidity and noninfringement positions

For a mature combination product, formulation patents are more likely to create litigation risk around a specific process or dosage form than to restore broad exclusivity over the product class.

What is the Orange Book status of PREMPRO?

PREMPRO is an FDA-approved small-molecule combination drug, not a biologic. Generic applicants would generally pursue an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The generic must show pharmaceutical equivalence and bioequivalence to the reference listed drug. [3,4]

Paragraph IV challenge risk

A Paragraph IV certification may arise if an ANDA applicant determines that an Orange Book-listed patent is invalid, unenforceable, or not infringed. The commercial consequences can include:

1. Notice to the NDA holder and patent owner.
2. Patent litigation within the statutory period.
3. A potential 30-month stay of FDA approval, subject to statutory conditions.
4. A possible 180-day period of generic exclusivity for the first qualifying applicant with a Paragraph IV certification.

The practical value of a Paragraph IV strategy depends on whether active patents remain listed and whether they cover commercially important strengths. For PREMPRO, the economic case is likely stronger for a low-cost, multi-strength generic platform than for a patent litigation campaign focused on legacy composition claims.

Which companies are challenging PREMPRO?

Generic competition for conjugated estrogen and medroxyprogesterone acetate products can come from manufacturers with experience in women’s health, hormone replacement therapy, and complex oral dosage forms. The competitive field may include:

• Established generic manufacturers
• Specialty pharmaceutical companies
• Contract development and manufacturing organizations
• Private-label suppliers
• Authorized-generic or licensed distribution partners

The identity and status of current ANDA applicants, tentative approvals, commercial launches, and patent certifications must be confirmed through FDA records and Orange Book data. A company can have an approved ANDA without actively marketing the product, so approval count alone does not measure competitive intensity. [4]

Does PREMPRO face biosimilar risk?

No. PREMPRO is not a biologic and does not face biosimilar substitution under the Public Health Service Act. Its relevant competitors are generic oral drug products approved through the ANDA pathway. [3]

The product does face substitution risk from other menopausal hormone therapies, including:

• Oral conjugated estrogens
• Oral estradiol products
• Transdermal estradiol
• Estradiol/progesterone products
• Estradiol/medroxyprogesterone products
• Selective estrogen receptor modulators in selected indications
• Nonhormonal therapies for vasomotor symptoms

These alternatives compete on safety perceptions, route of administration, dosing flexibility, payer coverage, and prescriber familiarity.

How strong is the PREMPRO patent estate?

The core PREMPRO patent estate is weak as a source of long-term exclusivity because the product has been marketed for decades and its original regulatory and patent protections are mature.

Patent strength is better assessed by claim category:

Claim category	Likely strategic strength
Basic combination of conjugated estrogens and medroxyprogesterone acetate	Low
Specific excipient composition	Moderate if technically narrow and well supported
Improved stability formulation	Moderate to high if unexpected data exist
Dissolution-controlled tablet	Moderate, but vulnerable to design-around
Manufacturing process	Moderate if process is difficult to replicate
Packaging system	Low to moderate
New route of administration	Potentially high, but requires clinical and regulatory investment
New indication	Potentially meaningful, but dependent on FDA approval and claim scope

An excipient patent has value only if it creates a measurable product advantage and restricts practical design-around options. A narrow claim covering a particular filler ratio may be easy to avoid. A broader claim tied to stability, dissolution, and bioequivalence performance is more commercially defensible but harder to obtain.

What commercial opportunities exist for PREMPRO excipients?

Generic cost reduction

The largest near-term opportunity is a lower-cost generic that uses a robust, scalable tablet platform. Savings may come from:

• Fewer manufacturing steps
• Lower coating weight
• Higher tablet-press speed
• Reduced batch failure
• Lower excipient cost
• Simplified packaging
• Regional manufacturing

In a mature market, manufacturing yield and supply reliability often matter more than a small change in excipient identity.

Private-label and contract manufacturing

A qualified formulation can support private-label supply to pharmacy chains, hospital systems, women’s-health distributors, and regional generic companies. The key commercial asset is a validated multi-strength platform with reliable supply of both active ingredients.

Patient-segmented products

Differentiated products could target:

• Patients seeking lactose-free tablets
• Patients who prefer calendar packaging
• Patients with swallowing difficulties
• Patients requiring lower estrogen strengths
• Patients receiving long-term therapy through managed-care plans

An orally disintegrating tablet or mini-tablet could improve administration, but it would require new development work and may face bioequivalence and stability challenges.

Combination-product expansion

A developer could use the formulation platform for related hormone products, such as:

• Estradiol/progestin combinations
• Lower-dose continuous regimens
• Sequential hormone therapy
• Alternative estrogen-progestogen ratios
• Region-specific strengths

The regulatory pathway would depend on whether the product is a generic equivalent, a reformulated product, or a new drug with clinical claims.

How does PREMPRO compare with competing hormone therapies?

Product type	Main advantage	Excipient or formulation opportunity	Competitive risk
PREMPRO oral combination	Established fixed-dose regimen	Lactose-free, lower-cost, improved packaging	Generic substitution and safety concerns
Oral estradiol	Flexible estrogen dosing	Broad strength and excipient platform	Strong generic competition
Transdermal estradiol	Avoids first-pass hepatic exposure	Adhesive, patch, gel, and pump systems	Device and formulation complexity
Estradiol/progesterone	Uses chemically defined actives	Capsule formulation and solubility control	Different clinical positioning
Sequential hormone therapy	Flexible cycle management	Calendar packs and co-packaging	Adherence complexity
Nonhormonal therapy	Avoids estrogen exposure	Modified-release and taste-masking systems	Different efficacy and patient populations

PREMPRO’s fixed combination simplifies prescribing for some patients but limits dose customization. That limitation creates an opportunity for products offering more flexible estrogen and progestin selection.

What litigation and settlement issues affect PREMPRO?

The most relevant litigation risks are likely to involve:

• Paragraph IV challenges to any active listed patents
• ANDA infringement claims
• Formulation or process patents
• Trade-secret disputes involving manufacturing
• Supply and licensing agreements
• Antitrust issues relating to delayed generic entry
• Product liability and labeling litigation

Settlement agreements can establish an agreed generic-entry date, licensing terms, authorized-generic rights, or restrictions on launch. Their economic value depends on the remaining market size and the number of potential entrants. A settlement involving an old product with limited remaining patent life may have less strategic value than a settlement tied to an improved formulation or high-volume strength.

What FDA regulatory issues apply to PREMPRO excipients?

FDA evaluates excipients through the finished-product application. An excipient used in an approved oral tablet does not automatically guarantee acceptability at a different concentration, in a new combination, or in a different dosage form.

Key regulatory considerations include:

• Inactive Ingredient Database status
• Maximum daily exposure
• Route and dosage-form precedent
• Impurity profile
• Elemental impurities
• Nitrosamine risk where relevant
• Residual solvents
• Microbial quality
• Color additive compliance
• Allergy and intolerance labeling
• Container-closure compatibility
• Stability under ICH conditions

For an ANDA, excipient differences from the reference product can be acceptable if they do not affect safety, performance, or bioequivalence and if the product meets applicable regulatory requirements. [3,5]

What geographic opportunities exist for PREMPRO alternatives?

The United States offers the clearest pathway through the ANDA system and Orange Book reference-product framework. Other markets may provide opportunities for:

• Local generic registration
• Government procurement
• Private-label hormone therapy
• Regional contract manufacturing
• Lower-cost excipient sourcing
• Strengths not commercialized in the United States

Geographic expansion must account for different reference products, excipient restrictions, labeling requirements, patent registers, pharmacopoeial standards, and hormone-therapy prescribing patterns.

The strongest geographic opportunity is usually a platform that can support several jurisdictions without major changes to excipient composition. That reduces validation, stability, and regulatory costs.

What generic launch scenarios exist for PREMPRO?

Launch scenario	Timing driver	Commercial outcome
First generic launch	ANDA approval and patent clearance	Highest initial price opportunity
Multiple generic launch	Several approved ANDAs	Rapid price erosion
Authorized generic	NDA-holder licensing or internal supply	Price competition with controlled distribution
Specialty generic	Differentiated excipients or packaging	Higher margin but narrower volume
Regional launch	Local registration and procurement access	Lower development cost, smaller market
Reformulated product	New clinical or formulation program	Longer development cycle and higher investment

Revenue exposure is concentrated in the size of the menopausal hormone-therapy market, the number of reimbursed prescriptions, and the availability of substitute products. A PREMPRO entrant should model revenue by strength, payer channel, generic price erosion, and switching from other estrogen-progestin therapies rather than relying on brand sales alone.

Key Takeaways

• PREMPRO is an oral fixed-dose combination of conjugated estrogens and medroxyprogesterone acetate.
• Its principal excipient platform includes lactose monohydrate, microcrystalline cellulose, magnesium stearate, hypromellose, and coating-related ingredients, subject to product-label revisions.
• Core patent and regulatory exclusivity are mature; commercial opportunity is centered on generic entry and formulation execution.
• The strongest excipient opportunities are lactose-free composition, improved blend uniformity, optimized lubrication, direct compression, coating efficiency, and moisture-protective packaging.
• PREMPRO is not subject to biosimilar competition. It competes with ANDA-approved generics and alternative menopausal hormone therapies.
• A patent strategy is more credible for stability, dissolution, manufacturing, or delivery improvements than for the basic estrogen-progestin combination.
• Commercial success will depend on multi-strength manufacturing, FDA bioequivalence, supply reliability, payer access, and price discipline.
• Formulation differentiation can support market positioning, but it will not create durable exclusivity unless supported by defensible patent claims and measurable product performance.

FAQs

Can a PREMPRO generic use different excipients from the reference product?

Yes. An ANDA applicant may use different inactive ingredients if the formulation meets FDA requirements and demonstrates equivalent quality, safety, and bioavailability.

Is a lactose-free PREMPRO formulation commercially attractive?

Potentially. It could address patients avoiding lactose and provide a simple differentiation strategy, but the formulation must preserve low-dose content uniformity, dissolution, stability, and tablet manufacturability.

Can an excipient change support a new patent for PREMPRO?

Yes, if the change produces a patentable composition, stability improvement, manufacturing advantage, or release profile that is nonobvious and adequately supported by data. A routine filler substitution is unlikely to provide strong protection.

Does PREMPRO require a biosimilar application?

No. PREMPRO is a small-molecule drug. A generic competitor would generally use the ANDA pathway rather than the biosimilar pathway.

Which PREMPRO strength is most important for a generic launch?

The commercial priority depends on prescription volume, payer demand, competitor availability, and manufacturing economics. A multi-strength launch generally provides better prescriber and pharmacy coverage than a single-strength product.

References

1. Pfizer Inc. (2024). PREMPRO prescribing information. U.S. Food and Drug Administration/DailyMed.

2. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

3. U.S. Food and Drug Administration. (2013). Guidance for industry: ANDAs for certain highly purified synthetic peptides. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. International Council for Harmonisation. (2009). Q8(R2): Pharmaceutical development. ICH.